PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announces that the American Society of Clinical Oncology (ASCO) has accepted three individual abstracts that highlight the utility and feasibility of the ChemoFx® Drug Response Marker for patients with gynecologic sarcomas, cervical cancer and ovarian cancer. These abstracts will be published in conjunction with ASCO’s 2012 Annual Symposium, being held June 1-5, 2012 in Chicago, Illinois.
The first abstract, titled, In Vitro Chemosensitivity Assay for Patients with Gynecologic Sarcoma, demonstrates whether ChemoFx can be used to help determine treatment decisions for patients with gynecologic sarcomas. Another abstract, titled, In Vitro Chemoresponse Assay for Patients with Cervical Cancer, shares the results of ChemoFx testing in primary, metastatic and recurrent cervical cancer. The third abstract titled, In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Women with Ovarian Cancer, determines whether in vitro platinum sensitivity rates are similar to published population response rates for ovarian cancer and examines differences in platinum sensitivity across histologic subtypes.
“We are very pleased with the outcomes to date from these three studies,” says Dr. Karl Williams, Chief Medical Director for Precision Therapeutics, Inc. “We look forward to watching these projects progress and further analyzing the value of ChemoFx for these difficult to treat patients.”
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.